Posted by Michael Wonder on 24 Sep 2016
CADTH publishes final recommendation for Lenvima (lenvatinib mesylate)
20 September 2016 - CADTH has posted its final outcome for Eisai's Lenvima.
CADTH has recommended the reimbursement of lenvatinib mesylate for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer on the condition that its cost-effectiveness is imrpved to an acceptable level.
